Sotyktu (deucravacitinib) vs Wezlana (ustekinumab-auub)
Sotyktu (deucravacitinib) vs Wezlana (ustekinumab-auub)
Sotyktu (deucravacitinib) is a novel oral medication that selectively inhibits the TYK2 enzyme, which is involved in the inflammatory process, and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Wezlana (ustekinumab-auub), on the other hand, is a subcutaneously administered biologic that targets interleukin-12 and interleukin-23, important cytokines in the pathogenesis of several inflammatory diseases, including plaque psoriasis. When deciding between Sotyktu and Wezlana, one should consider factors such as the route of administration (oral vs injection), the mechanism of action, the specific indications approved by regulatory agencies, potential side effects, and how the medication fits with their lifestyle and treatment preferences.
Difference between Sotyktu and Wezlana
Metric | Sotyktu (deucravacitinib) | Wezlana (ustekinumab-auub) |
---|---|---|
Generic name | Deucravacitinib | Ustekinumab-auub |
Indications | Plaque psoriasis | Plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Mechanism of action | Tyrosine kinase 2 (TYK2) inhibitor | Interleukin-12 and -23 (IL-12 and IL-23) inhibitor |
Brand names | Sotyktu | Wezlana |
Administrative route | Oral | Subcutaneous injection |
Side effects | Upper respiratory infections, increased blood creatine phosphokinase, herpes simplex, folliculitis, acne, headache | Upper respiratory infections, headache, fatigue, diarrhea, injection site reactions |
Contraindications | None currently known | Patients with clinically significant hypersensitivity to ustekinumab or any excipients |
Drug class | Selective immunosuppressant | Monoclonal antibody |
Manufacturer | Bristol Myers Squibb | Janssen Biotech, Inc. |
Efficacy
Efficacy of Sotyktu (deucravacitinib) in Treating Psoriasis
Sotyktu, with the generic name deucravacitinib, is a novel oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. As a selective tyrosine kinase 2 (TYK2) inhibitor, Sotyktu works by modulating the immune response that contributes to the inflammation characteristic of psoriasis. Clinical trials have demonstrated that Sotyktu significantly improves skin clearance compared to placebo, with a notable percentage of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score. The efficacy of Sotyktu has been established through rigorous phase 3 trials, showcasing its potential as a first-in-class oral treatment option for psoriasis.
Efficacy of Wezlana (ustekinumab-auub) in Treating Psoriasis
Wezlana, a biosimilar to the reference product Stelara, contains the active substance ustekinumab-auub and is used to treat moderate-to-severe plaque psoriasis in adults. Ustekinumab is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines known to play a role in inflammatory and immune responses. By inhibiting the action of these cytokines, Wezlana effectively reduces the signs and symptoms of psoriasis. Clinical studies have shown that Wezlana is highly effective in achieving skin clearance, with a significant number of patients reaching PASI 75, and even PASI 90 (90% reduction in PASI score), indicating substantial improvement in skin lesions.
Both Sotyktu and Wezlana represent important treatment options for patients with psoriasis, offering different mechanisms of action and administration routes. Sotyktu, as an oral medication, provides an alternative to injectable treatments, potentially improving patient adherence and convenience. Wezlana, as a biosimilar, offers a more cost-effective treatment option with demonstrated efficacy that is similar to its reference product. The choice of treatment may depend on various factors, including disease severity, patient preference, previous treatment response, and potential side effects.
It is important for healthcare providers to consider the individual needs of each patient when prescribing treatments for psoriasis. Both Sotyktu and Wezlana have undergone extensive clinical testing to establish their efficacy and safety profiles. As with all medications, the benefits and risks should be weighed, and treatment should be tailored to achieve the best possible outcomes for patients with psoriasis.
Regulatory Agency Approvals
Sotyktu
Wezlana
Access Sotyktu or Wezlana today
If Sotyktu or Wezlana are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us